KR880007495A - 5-아릴-3h-1,2,4-트리아졸-3-온 및 신경변성 질환의 치료에 있어서의 그들의 용도 - Google Patents
5-아릴-3h-1,2,4-트리아졸-3-온 및 신경변성 질환의 치료에 있어서의 그들의 용도 Download PDFInfo
- Publication number
- KR880007495A KR880007495A KR870014559A KR870014559A KR880007495A KR 880007495 A KR880007495 A KR 880007495A KR 870014559 A KR870014559 A KR 870014559A KR 870014559 A KR870014559 A KR 870014559A KR 880007495 A KR880007495 A KR 880007495A
- Authority
- KR
- South Korea
- Prior art keywords
- treated
- ethyl
- methyl
- hydrogen
- triazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (15)
- 치료량의 하기 일반식(I)의 화합물 및 Ar가 질소-함유 헤테로사이클릭 잔기인 화합물의 약제학적으로 허용되는 염을 투여함을 특징으로 하여 신경성 질환을 치료하는 방법.상기식에서, Ar은 페닐, 나프틸 또는 헤테로사이클릭 잔기이며, R1은 수소 또는 C1-6저급 알킬이고, R2는 C1-6저급 알킬이며, R은 C1-6알킬, C1-6알콕시, 하이드록시, 할로게노, 또는 트리플루오로메틸이고, n은 0,1 또는 2이거나, Rn-(Ar)이 메틸렌디옥시페닐이고, m은 0,1 또는 2이다.
- 제1항에 있어서, Ar이 페닐인 방법.
- 제1항에 있어서, m이 0인 방법.
- 제1항에 있어서, R1이 수소, 메틸 또는 에틸인 방법.
- 제1항에 있어서, R2이 메틸 또는 에틸인 방법.
- 제1항에 있어서, Ar이 페닐이고, m이 0이며, R이 할로게노인 방법.
- 제6항에 있어서, R이 클로로인 방법.
- 제6항에 있어서, Rn-(Ar)-(CH2)m 이 4-클로로페닐이고, R1이 메틸이며, R2가 에틸인 방법.
- 제6항에 있어서, Rn-(Ar)-(CH2)m 이 4-클로로페닐이고, R1이 수소이며, R2가 에틸인 방법.
- 제6항에 있어서, Rn-(Ar)-(CH2)m 이 2-클로로페닐이고, R1이 수소이며, R2가 메틸인 방법.
- 제1항에 있어서, 발작을 치료하는 방법.
- 제1항에 있어서, 뇌빈혈를 치료하는 방법.
- 제1항에 있어서, 파킨슨 증후군을 치료하는 방법.
- 제1항에 있어서, 알쯔하이머(Alzheimer)병을 치료하는 방법.
- 제1항에 있어서, 헌팅톤(Huntington)병을 치료하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94463486A | 1986-12-19 | 1986-12-19 | |
US944634 | 1986-12-19 | ||
US10700187A | 1987-10-16 | 1987-10-16 | |
US107001 | 1987-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR880007495A true KR880007495A (ko) | 1988-08-27 |
Family
ID=26804275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR870014559A KR880007495A (ko) | 1986-12-19 | 1987-12-19 | 5-아릴-3h-1,2,4-트리아졸-3-온 및 신경변성 질환의 치료에 있어서의 그들의 용도 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0273309B1 (ko) |
JP (1) | JP2593084B2 (ko) |
KR (1) | KR880007495A (ko) |
AT (1) | ATE116851T1 (ko) |
DE (1) | DE3750979T2 (ko) |
DK (1) | DK172668B1 (ko) |
ES (1) | ES2069528T3 (ko) |
GR (1) | GR3015685T3 (ko) |
IE (1) | IE65857B1 (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966909A (en) * | 1989-12-20 | 1990-10-30 | Merrell Dow Pharmaceuticals | 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants |
AU644500B2 (en) * | 1990-12-20 | 1993-12-09 | Merrell Dow Pharmaceuticals Inc. | 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma |
US5840746A (en) * | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
DE19816882A1 (de) * | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Triazolone mit neuroprotektiver Wirkung |
TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
US8293778B2 (en) | 2004-07-27 | 2012-10-23 | Roche Palo Alto Llc | Heterocyclic antiviral compounds |
CN1993332B (zh) | 2004-07-27 | 2011-04-06 | 弗·哈夫曼-拉罗切有限公司 | 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物 |
CN101657433A (zh) | 2007-03-29 | 2010-02-24 | 弗·哈夫曼-拉罗切有限公司 | 非核苷逆转录酶抑制剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1126882B (de) * | 1960-05-03 | 1962-04-05 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von 1,2,4-Triazolonen-(5) |
BE621842A (ko) * | 1962-08-27 | |||
DE1545646B1 (de) * | 1965-12-15 | 1969-09-18 | Boehringer Sohn Ingelheim | 1,3-Dimethyl-4-(2',4'-dichlorphenyl)-1,2,4-triazolon-(5) und Verfahren zu dessen Herstellung |
DD153953A3 (de) * | 1980-04-01 | 1982-02-17 | Gottfried Schuster | Mittel zur chemotherapie von virosen der kulturpflanzen |
DD160447A1 (de) * | 1981-03-26 | 1983-08-03 | Johannes Dost | Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten |
AR243171A1 (es) * | 1985-10-29 | 1993-07-30 | Merrell Pharma Inc | Procedimiento para preparar 5-aril-2,4-dialquil-3h-1,2,4-triazol-3-tionas. |
-
1987
- 1987-12-15 JP JP62315427A patent/JP2593084B2/ja not_active Expired - Lifetime
- 1987-12-17 AT AT87118727T patent/ATE116851T1/de not_active IP Right Cessation
- 1987-12-17 EP EP87118727A patent/EP0273309B1/en not_active Expired - Lifetime
- 1987-12-17 ES ES87118727T patent/ES2069528T3/es not_active Expired - Lifetime
- 1987-12-17 DE DE3750979T patent/DE3750979T2/de not_active Expired - Fee Related
- 1987-12-18 DK DK198706711A patent/DK172668B1/da not_active IP Right Cessation
- 1987-12-18 IE IE345987A patent/IE65857B1/en not_active IP Right Cessation
- 1987-12-19 KR KR870014559A patent/KR880007495A/ko not_active Application Discontinuation
-
1995
- 1995-04-04 GR GR950400832T patent/GR3015685T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
GR3015685T3 (en) | 1995-07-31 |
ATE116851T1 (de) | 1995-01-15 |
EP0273309A3 (en) | 1991-01-09 |
EP0273309B1 (en) | 1995-01-11 |
DK671187A (da) | 1988-06-20 |
IE65857B1 (en) | 1995-11-29 |
DK172668B1 (da) | 1999-05-10 |
JP2593084B2 (ja) | 1997-03-19 |
DE3750979D1 (de) | 1995-02-23 |
EP0273309A2 (en) | 1988-07-06 |
DE3750979T2 (de) | 1995-05-24 |
DK671187D0 (da) | 1987-12-18 |
JPS63170312A (ja) | 1988-07-14 |
IE873459L (en) | 1989-04-16 |
ES2069528T3 (es) | 1995-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO960380D0 (no) | Middel til behandling av neurosykdommer | |
KR910014350A (ko) | 3-아미노피페리딘 유도체 및 관련 질소 함유 헤테로사이클릭 화합물 | |
RU94043806A (ru) | Производные оксазолидин-2-он | |
KR950010888A (ko) | 평활근세포 증식 및 재발협착증을 억제하는 방법 | |
RU94044671A (ru) | Применение непептидных антагонистов рецептора тахикинина | |
NO152902C (no) | Analogifremgangsmaae for fremstilling av terapeutisk virksomme 1-alkyl-2-aminotetralinderivater | |
PT669920E (pt) | 3-aminoalquilamino-1,2-benzoxazoles substituidos ecompostos relacionados | |
KR950701223A (ko) | 항허혈성(Anti-ichemic)약물 | |
KR940005274A (ko) | 쇼그렌(Sjoegren)증후군 치료제 | |
KR930005972A (ko) | N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민 | |
KR890011596A (ko) | 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도 | |
KR950016727A (ko) | 트롬보모듈린 발현을 증가시키는 방법 | |
KR880007495A (ko) | 5-아릴-3h-1,2,4-트리아졸-3-온 및 신경변성 질환의 치료에 있어서의 그들의 용도 | |
ATE79257T1 (de) | Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden. | |
KR940018094A (ko) | 모르피난의 0-아릴 에테르 | |
KR880007494A (ko) | 5-아릴-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그들의 용도 | |
KR950701623A (ko) | 치환된 헥사하이드로벤조페난트리딘 | |
ATE99934T1 (de) | Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten. | |
FI923759A (fi) | Terapeutiska bensazapinfoereningar | |
KR910011807A (ko) | 4-벤질-5-페닐-2,4-디히드로-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그 의 용도 | |
KR900012903A (ko) | 피롤리딘 화합물 및 약제학적 용도 | |
KR960003719A (ko) | 녹내장 치료제 및 안압 강하제 | |
ES2086528T3 (es) | Nuevos compuestos biciclicos sustituidos con amino. | |
KR950016720A (ko) | 아밀로이드 단백질의 효과를 저해하는 방법 | |
KR910006292A (ko) | 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |